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Abstract
Background: Long-term regular clinic follow up is an important component of HIV care. We determined the
frequency and characteristics of HIV-infected patients lost to follow up from a London HIV clinic, and factors
associated with loss to all HIV follow up in the UK.
Methods: We identified 1859 HIV-infected adults who had registered and attended a London clinic on one or more
occasions between January 1997 and December 2005. Loss to follow up was defined as clinic non-attendance for
one or more years. Through anonymized linkage with the Survey of Prevalent HIV Infections Diagnosed and Health
Protection Scotland, national databases of all HIV patients in care in the UK up to December 2006, loss-to-follow-up
patients were categorized as Transfers (subsequently received care at another UK HIV clinic) or UKLFU (no record of
subsequent attendance at any HIV clinic in the UK). Logistic regression analysis was used to identify factors
associated with UKLFU for those both on highly active antiretroviral therapy (HAART) and not on HAART.
Results: In total, 722 (38.8%) of 1859 patients were defined as lost to follow up. Of these, 347 (48.1%) were
Transfers and 375 (51.9%), or 20.2% of all patients, were UKLFU. Overall, 11.9% of all patients receiving HAART, and
32.2% not receiving HAART were UKLFU. Among those on HAART, risk factors for UKLFU were: African heterosexual
female (OR = 2.22, 95% CI: 1.11-4.56) versus white men who have sex with men; earlier year of HIV clinic
registration (1997-1999 OR: 3.51, 95% CI: 1.97-6.26; 2000-02 OR: 2.49, 95% CI: 1.43-4.32 vs. 2003-2005); CD4 count of
< 200 versus > 350 cells/mm
3 (OR = 1.99, 95% CI:1.05-3.74); and a detectable viral load of > 400 copies/ml
(OR = 5.03, 95% CI: 2.95-8.57 vs. ≤ 400 copies/ml) at last clinic visit.
Among those not receiving HAART, factors were: African heterosexual male (OR = 3.91, 95% CI: 1.77-8.64) versus
white men who have sex with men; earlier HIV clinic registration (2000-2002 OR: 2.91, 95% CI: 1.77-4.78; 1997-1999:
OR: 5.26, 95% CI: 2.71-10.19); and a CD4 count of < 200 cells/mm
3 (OR: 3.24, 95% CI: 1.49-7.04).
Conclusions: One in five HIV-infected patients (one in three not on HAART and one in nine on HAART) from a
London clinic were lost to all clinical follow up in the UK. Black African ethnicity, earlier year of clinic registration
and advanced immunological suppression were the most important predictors of UKLFU. There is a need for all
HIV clinics to establish systems for monitoring and tracing loss-to-follow-up patients, and to implement strategies
for improving retention in care.
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The widespread availability of highly active antiretroviral
therapy (HAART) has transformed the prognosis of HIV-
infected patients over the past 10 years [1,2]. However,
while there has been a marked reduction in HIV-related
mortality and morbidity [2,3], additional challenges have
emerged in the long-term management of HIV, such as
drug toxicities [4-6], treatment failure due to poor adher-
ence [7,8] and/or drug resistance [9] requiring regimen
change, and increasing non-HIV-related morbidity and
mortality [10-12]. As with any chronic illness, HIV
patients require long-term, regular clinical follow up to
monitor disease progression and optimal timing of initia-
tion of HAART, assess response and adherence to antire-
troviral therapy and associated adverse events, and
address sexual health and HIV prevention needs [13].
Long-term retention is therefore an important compo-
nent of HIV care, and high rates of loss to follow up
would compromise the effective delivery of HIV care, as
well as reliable documentation of mortality.
Rates of adherence [7], virological suppression [14] and
survival [14,15] are the most commonly reported mea-
sures of the effectiveness of HAART management, but
this applies only to patients who remain under follow up
and in care. Although there have been several studies on
losses to follow up from HAART programmes across
sub-Saharan Africa [16-20], until recently there had been
a paucity of information on losses to follow up from HIV
care in high-income countries [21-26]. Most of these stu-
dies were conducted prior to the widespread use of
HAART [23,25,26] or in research cohorts [27-29].
Furthermore, since many clinics do not have established
systems for identifying patients who are lost to follow up
(LFU), there is need for a greater understanding of the
rates and reasons for loss to follow up to develop strate-
gies to optimize retention.
We undertook an evaluation of the frequency of LFU
and characteristics of patients who were LFU among
adult HIV-infected patients attending a large HIV clinic
in south London. We then matched those patients who
were LFU with the national databases of all HIV
patients receiving care in the UK to establish whether
patients were LFU due to transfer to another clinic in
the UK, or were lost to all follow up in the UK, and the
factors associated with this.
Methods
Study population
HIV care and treatment in the UK is delivered through
227 specialist treatment sites, of which King’s College
Hospital is the eighth largest clinic nationally and the
second largest in south London (personal communica-
tion Chau Cuong, Survey of Prevalent HIV Infections
Diagnosed, Health Protection Agency). The clinic is
based in south-east London, which has the highest rate
of new HIV diagnoses in the UK, accounting for
approximately 10% of all new HIV diagnoses in 2006
[30]. The clinic population is also highly ethnically
diverse - of 500 new HIV diagnoses between 1998 and
2000, 54.7% were in black Africans (34.8% from eastern
Africa, 32.8% from west Africa, and 32.4% from south-
east Africa) and 9.1% in black Caribbeans.
Identification and definition of loss to follow up
We identified all HIV-1 infected patients (≥ 18 years)
who registered and attended the King’s College Hospital
HIV clinic on at least one occasion over a nine-year per-
iod (between 1 January 1997 and 31 December 2005),
and reviewed their follow-up records up to 31 Decem-
ber 2006. The day, 1 January 1997, was identified as the
initial date for the selection of the study population as
by this date, HAART was widely available, and we
wished to avoid the potential bias of availability of
HAART on losses to follow up.
These patients were categorized as either LFU or cur-
rent clinical attendees (CCAs). LFU was defined as non-
attendance at the Kings College Hospital clinic for at
least one year (up to 31 December 2006); at this clinic,
routine follow up is in general every three months for
patients on HAART, and every three to six months for
those not yet on HAART. CCAs were defined as those
patients who remained under King’s College Hospital
clinic follow up as of 31 December 2006.
Patients defined as LFU were then matched against
two national registers of HIV patients receiving care in
t h eU K :t h eS u r v e yo fP r e v a l e n tH I VI n f e c t i o n sD i a g -
nosed (SOPHID), which covers England, Wales and
Northern Ireland; and the Health Protection Scotland
database. The intention was to determine if these LFU
patients had received care elsewhere in the UK between
1 January 1997 and 31 December 2006 (or 30 June 2007
for London SOPHID). Records were linked by matching
on three criteria: soundex code of surname, sex and
date of birth [31]. Additional matches were obtained
through the use of less stringent criteria, called “fuzzy
matching”, using part-soundex code (first two characters
of the four-character code) to overcome misspelling of
surnames, and sex and date of birth. All data were
anonymized to preserve the patients’ identity, and their
subsequent treatment locations were not identified.
For each LFU patient, we determined whether they had
either subsequently registered and received care at
another HIV clinic in the UK, and were therefore only
LFU from King’s College Hospital (Transfers), or had not
registered at any other UK HIV clinic and were therefore
lost to all clinical follow up in the UK (UKLFU). In order
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(as reports on deaths for clinic attendees are based on
passive reporting only), we also matched all LFU patients
against the Office of National Statistics register of deaths
in England, Wales and Northern Ireland for persons aged
60 years or younger, and through Health Protection Scot-
land using soundex code, sex and date of birth.
We matched our female UKLFU with the National
Study of HIV in Pregnancy and Childhood using soun-
dex code, date of birth, date of HIV diagnosis and coun-
try of birth in order to ascertain whether these patients
may have been seen elsewhere for antenatal care subse-
quent to leaving the King’s College Hospital HIV clinic.
We also determined whether their HAART therapy was
for the prevention of mother to child transmission
alone. Finally, as a supplementary exercise, we reviewed
the medical records for those defined as UKLFU to
identify any documentation of intent to leave the UK, or
other indications of reasons for LFU, and so further
inform our proposed strategies for addressing UKLFU.
Statistical analyses
Demographic and clinical information, including gender,
risk group, ethnicity, serial CD4 cell count and viral
load, HAART history and dates of all clinic visits, were
obtained from the HIV clinic electronic database for all
patients. We compared the clinical characteristics of
patients LFU from King’s College Hospital HIV clinic
(Transfers) and the UK (UKLFU), with all current clinic
a t t e n d e e s( C C A s )a tt h eK i n g ’s College Hospital HIV
clinic using Chi square or Fisher’s exact tests for catego-
rical variables, and Kruskal-Wallis rank test for continu-
ous variables. Univariate and multivariate logistic
regression analyses were performed to identify factors
associated with UKLFU versus CCAs. Key variables
included in the models were: year of clinic registration;
age at HIV diagnosis; gender; risk group; ethnicity; use
of HAART; initial clinical stage and CD4 count at clinic
registration and also prior to LFU (or 31 December
2006 for those who were CCAs); and viral load at last
visit prior to LFU for those on HAART.
We also repeated our analyses using a clinically rele-
vant composite variable of gender-risk group and ethni-
city, for descriptive (Figure 1 and Table 1) and adjusted
analyses (Tables 2 and 3) to help identify the sub-group
at greatest risk of UKLFU and to inform strategies to
reduce UKLFU. Since we hypothesized that factors asso-
ciated with LFU would differ according to whether
patients were receiving HAART, analyses were further
stratified according to whether they had been prescribed
HAART within six months of their last clinic appoint-
ment prior to LFU, or at 31 December 2006 for those
who were CCAs. All statistical analyses were performed
using STATA 10.0 software (STATA Corp., Texas,
USA).
Results
There were 1859 HIV-positive patients aged 18 years or
older who had registered and attended the King’s
College Hospital HIV clinic on at least one occasion
over a nine-year period (between 1 January 1997 and 31
December 2005). Overall, there were 625 (33.6%) black
African or Caribbean women and 348 (18.7%) black
African or Caribbean men, and 445 (23.9%) white men
who have sex with men (MSM). Less than 5% were
either white heterosexual men or women. The median
age at HIV diagnosis was 32 years (IQR 27-37).
In all, 432 (23.2%) patients were registered at the
King’s College Hospital HIV clinic between 1997 and
1999, 666 (35.8%) between 2000 and 2002, and 761
(40.9%) between 2003 and 2005. The initial median CD4
cell count was 303 (IQR: 141-467). In total, 762 (40.1%)
had been prescribed HAART within six months of their
last clinic visit. Those prescribed HAART within six
months of their last clinic visit were more likely to be
white than those who had not received HAART, even
after adjustment for CD4 count, but there was no signif-
icant difference in gender or risk group.
A total of 722 (38.8%) of 1859 patients were defined as
LFU as they had not been seen at the clinic for a year or
longer (23.3% and 61.1%, respectively, for those receiv-
ing and not receiving HAART; Figure 2). Of these 722,
347 (48.1%), or 18.7% of all registered patients, were
defined as Transfers (49.2% and 47.4% of those patients
LFU receiving or not receiving HAART, respectively) as
they had subsequently been seen at another HIV clinic
in the UK, and 12 of these (3.5%) had died.
In total, 375 (51.9% of 722 LFU patients, or 20.2% of the
1859 eligible clinic population) were defined as UKLFU
because there was no record of any further clinical follow
up in the UK (50.8% and 52.6% of those patients LFU
receiving or not receiving HAART, respectively). Overall,
nine (2.4%) had died. After exclusion of 33 deceased
patients (12 CCAs, 12 Transfers and nine UKLFU), subse-
quent analyses were based on the remaining 366 UKLFU
patients (125 on HAART and 241 not on HAART) appar-
ently lost to all follow up in the UK, and therefore at the
greatest risk of subsequent HIV-related morbidity and
mortality.
Frequency of LFU according to gender-ethnicity risk
group
Figure 1 shows the percentages of Transfers (n = 326)
and UKLFU (n = 360) according to eight ethnicity-
gender HIV risk group categories. The highest percen-
tage of Transfers to another HIV clinic in the UK was
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(24.1%), black African or Caribbean MSM (17.1%), and
white heterosexual men (15.1%). In contrast, UKLFU
was lowest among white and black MSM (11.2% and
14.3%, respectively), and white women (14.8%); it was
highest among black Caribbean (29.3%) and African
(26.2%) men, followed by black Caribbean and African
women (23.4% and 22.1%, respectively).
Characteristics of Transfers and UKLFU versus current
clinic attendees
Table 1 compares the demographic and clinical charac-
teristics of current clinic attendees with Transfers and
UKLFU after exclusion of the 33 patients who were
known to have died. There was a higher proportion of
white MSM (39.2%) among Transfers, compared with
UKLFU (14.2%) or CCAs (23.3%, p < 0.001), while
UKLFU had a higher proportion of black African het-
erosexual men (21.3%) compared with Transfers
(11.2%) or CCAs (15.6%). A greater percentage of
CCAs first registered for HIV care at the Kings College
Hospital HIV clinic between 2003 and 2005 than
Transfers and UKLFU (49.2% vs. 29.2% and 28.7%,
respectively, p < 0.001).
There were no significant differences between the
groups in baseline clinical stage, but there was a
statistically significant trend towards higher CD4 counts
for UKLFU, Transfers and CCAs (348 vs. 322 vs. 289
cells/mm
3, respectively). The UKLFU group had a much
lower percentage receiving HAART than CCAs (34.2%
vs. 74.1%, p < 0.001) and a corresponding lower CD4
count prior to loss to follow up (p < 0.001). The median
duration of follow up was 46.2 months (IQR 26.3-72.3)
for CCAs, 7.7 months (IQR 1.2-24.3) for Transfers and
4.1 months (IQR 0.7-19.1) for UKLFU (p < 0.001) (2.2
months (IQR 0-14.7) for those not on HAART, and 9.9
months of follow up (IQR 3.0-27.9) for those recently
prescribed HAART). Overall, 38.4% (n = 149) of
UKLFU patients had made two or less clinic visits in the
year prior to becoming LFU (19.2% for those on
HAART and 48.5% not on HAART) compared with
31.9% of Transfers (p < 0.001).
Factors associated with LFU among those receiving or
not receiving HAART
Overall, in a multivariate analysis, the factors most
strongly associated with the UKLFU group versus the
CCAs group were: not receiving HAART versus current
HAART use (OR = 2.14, 95% CI: 1.14 to 3.27); being a
black African heterosexual man (OR = 1.91, 95% CI: 1.08
to 3.35) or black African heterosexual woman (OR = 1.93,
95% CI: 1.18 to 3.15) versus white MSM; earlier clinic
Figure 1 Percentage of Ethnicity-Gender HIV Risk groups LFU
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7.57) and 2000 to 2002 (OR = 2.90, 95% CI: 1.96 to 4.30)
versus registration in 2003 to 2005; a CDC code of E1
(asymptomatic HIV) (OR = 1.92, 95% CI: 1.14 to 3.24);
having a low CD4 count of < 200 versus > 350 cells/mm
3
(OR = 2.30, 95% CI: 1.14 to 3.24), and a detectable viral
load of > 400 versus ≤ 400 copies/ml (OR = 3.86, 95% CI:
2.59 to 5.73) at last attendance.
After stratification according to HAART use, indepen-
dent risk factors for UKLFU among those receiving
HAART were: black African heterosexual female versus
MSM (OR = 2.22, 95% CI: 1.11 to 4.56); earlier HIV
clinic registration (1997-1999 OR = 3.51, 95% CI: 1.97
to 6.26; 2000-2002 OR = 2.49, 95% CI: 1.43 to 4.32) ver-
sus 2003-2005; a CD4 cell count of < 200 cells/mm
3
versus > 350 cells/mm
3 (OR = 1.99, 95% CI: 1.05 to
3.74); and a detectable viral load (OR = 5.03, 95% CI:
2.95 to 8.57) at last attendance.
Among those not receiving HAART, independent risk
factors for UKLFU were: black African heterosexual
male (OR = 3.91, 95% CI: 1.77 to 8.64); earlier clinic
registration in 1997-1999 (OR = 5.26, 95% CI:
Table 1 Characteristics of 1826 eligible HIV-positive King’s College Hospital patients between 1 January 1997 and 31
December 2005 on ≥ 1 occasion
ǂ
CCAs TRANSFERS UKLFU P value
n = 1125* n = 335* n = 366*
Median age at HIV clinic registration (years) (IQR) 33 (27-38) 30 (26-35) 31 (26-36) < 0.001
Gender-ethnicity risk group n = 1119 n = 314 n = 352
White MSM 261 (23.3%) 123 (39.2%) 50 (14.2%)
Black African/Caribbean MSM 48 (4.3%) 12 (3.8%) 9 (2.6%)
Black African heterosexual female 362 (32.4%) 72 (22.9%) 123 (34.9%)
Black African heterosexual male 175 (15.6%) 35 (11.2%) 75 (21.3%) < 0.001
Black Caribbean heterosexual female 43 (3.8%) 6 (1.9%) 14 (4.0%)
Black Caribbean heterosexual male 39 (3.5%) 2 (0.6%) 16 (4.6%)
White heterosexual female 33 (2.9%) 13 (4.1%) 8 (2.3%)
White heterosexual male 36 (3.2%) 7 (2.2%) 8 (2.3%)
Other
† 122 (10.9%) 44 (14.0%) 49 (13.9%)
Year of HIV clinic registration
1997-1999 219 (19.5%) 95 (28.4%) 103 (28.1%)
2000-2002 353 (31.4%) 142 (42.4%) 158 (43.2%) < 0.001
2003-2005 553 (49.2%) 98 (29.2%) 105 (28.7%)
Median baseline† CD4 cell count, cells/mm
3 (IQR) cells/mm
3 289 (134-459) 322 (194-480) 348 (145-523) 0.001
Baseline** CDC stage n = 1125 n = 303 n = 322
Asymptomatic 734 (65.2%) 185 (61.1%) 224 (69.6%) 0.091
Symptomatic 232 (20.6%) 80 (26.4%) 61 (18.9%)
AIDS 159 (14.1%) 38 (12.5%) 37 (11.5%)
Received HAART within 6 months of last visit 834 (74.1%) 118 (35.2%) 125 (34.2%) < 0.001
Median CD4 cell count at last visit, cells/mm
3 (IQR) 410 (299-559) 376 (229-520) 368 (229-551) < 0.001
% with CD4 cell count < 200 cells/mm
3 at last visit n = 1112 n = 246 n = 289
109 (9.8%) 48 (19.5%) 64 (22.2%) < 0.001
Median log viral load, copies/ml, at last visit (IQR) 1.6 (1.6-2.3) 3.7 (1.7-4.7) 3.5 (2.0-4.3) < 0.001
% with VL ≤ 400 copies/ml at last attendance n = 1109 n = 235 n = 266 < 0.001
855 (77.1%) 88 (37.4%) 90 (33.8%)
Median duration of clinic attendance (months) 46.2 (26.3-72.3) 7.7 (1.2-24.3) 4.1 (0.7-19.1) < 0.001
Number of clinic visits in year prior to last clinic visit n = 1114 n = 326 n = 362
≤ 2 25 (2.2%) 104 (31.9%) 149 (38.4%) < 0.001
All percentages are column percentages; ǂ of the original 1,859 patients, 33 were deceased (9 UKLFU patients, 12 Transfers and 12 CCAs) and excluded from
further analysis, leaving 1826 patients.
* Denominator values may differ due to missing data; †“ other” gender-ethnic-risk group includes MSM and heterosexuals from other ethnic groups, such as
Asian, black other, mixed (n = 122), and patients who acquired HIV through intravenous drug use (n = 82) and blood products/surgery (n = 6). ** Baseline refers
to the first CD4 measurement and first reported CDC stage.
CCAs: current clinic attendees. Transfers: patients not seen at the KCH HIV clinic for at least 1 year, but who subsequently have been seen elsewhere forH I V
treatment/care services in the UK. UKLFU: patients not seen at the King’s College Hospital HIV clinic for at least 1 year, who have not been seen anywhere else
for HIV treatment/care services in the UK for at least a year.
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4.78); and a CD4 cell count of < 200 cells/mm
3 prior to
loss to follow up (OR = 3.24, 95% CI: 1.49 to 7.04).
Medical notes review
We reviewed the medical records of UKLFU for any
documentation that might indicate reasons for being
LFU in the UK, and so inform strategies to reduce loss
to follow up. Of 366 UKLFU patients, 294 (80.3%) had
their medical records located, and in 196 of these
(66.7%), there was relevant documentation. Overall, in
more than half (n = 115, 58.7%), there was an indica-
tion that they planned to leave the UK, either as a
planned voluntary departure (n = 79, 40.3%) or
because they were at risk of deportation because of
documented immigration problems (n = 36, 18.4%). A
further nine (4.6%) patients were documented to be in
denial about their HIV status, and were not seen again
following their initial HIV diagnosis.
Discussion
In this first systematic study of losses to follow up in a
UK HIV clinic, we found that 38.8% of 1859 HIV
patients (23.3% on HAART and 61.1% not on HAART),
w h ow e r er e g i s t e r e da tal a r g ei n n e r - c i t yc l i n i co v e ra
nine-year period, discontinued their follow up at the
clinic. Linkage with the national database of all HIV
patients receiving care in the UK indicated that about
half had transferred their care to another clinic in the
UK, and the remaining half (20% of all registered
patients; 11.9% of those patients receiving HAART, and
32.2% not receiving HAART) received no further HIV
care in the UK. This percentage was highest among
black African and Caribbean heterosexual men, with
more than a quarter in these groups (26.2% and 29.3%,
respectively) lost to all UK HIV care and follow up.
Approximately one-third of those lost to all UK care
were receiving antiretroviral therapy prior to being LFU,
and only 2.4% of UKLFU could be attributed to deaths
in the UK.
Our overall rate of one in five becoming lost to UK
follow up (after exclusion of deaths) was higher than the
8.5% [21] and 11.9% [23] from two cohorts in France,
but was comparable to the 25% reported by an Italian
cohort with a high proportion of injecting drug users
[26], the 27% reported by a Boston clinical cohort [22],
Table 2 Univariate & multivariate logistic regression for UKLFU vs. CCAs - on HAART (n = 959)
n (%)* Univariate OR (95% CI ) P value Multivariate OR (95% CI) P value
Age at HIV clinic registration (per year older) 959 0.99 (0.97-1.01) 0.308 - -
Gender-ethnicity risk group n = 956
White MSM 205 (21.4%) 1.00 (REF) 1.00 (REF)
Black African/Caribbean MSM 32 (3.4%) 1.41 (0.38-5.21) 0.605 1.48 (0.38-5.82) 0.575
Black African heterosexual female 327 (34.2%) 2.46 (1.32-4.58) 0.004 2.22 (1.11-4.56) 0.025
Black African heterosexual male 184 (19.2%) 2.66 (1.36-5.19) 0.004 1.31 (0.59-2.94) 0.505
Black Caribbean heterosexual female 27 (2.8%) 1.71 (0.46-6.37) 0.427 2.04 (0.49-8.46) 0.328
Black Caribbean heterosexual male 35 (3.7%) 2.27 (0.76-6.77) 0.140 2.25 (0.68-7.44) 0.186
White heterosexual female 25 (2.6%) 1.86 (0.50-6.98) 0.358 0.76 (0.09-6.46) 0.804
White heterosexual male 32 (3.4%) 2.53 (0.84-7.57) 0.098 2.70 (0.79-9.18) 0.113
Other 89 (9.3%) 1.92 (0.84-4.46) 0.123 1.76 (0.69-4.51) 0.237
Year of KCH HIV clinic registration n = 959 0.82 (0.76-0.89) < 0.001 0.81 (0.74-0.88) < 0.001
2003-2005 403 (42.0%) 1.00 (REF) 1.00 (REF)
2000-2002 320 (33.4%) 2.76 (1.69-4.51) < 0.001 2.49 (1.43-4.32) 0.001
1997-1999 236 (24.6%) 3.28 (1.97-5.45) < 0.001 3.51 (1.97-6.26) < 0.001
CDC stage prior to LFU
ǂ n = 950
AIDS 266 (28.0%) 1.00 (REF) - -
Symptomatic 400 (42.1%) 1.45 (0.86-2.44) 0.160 - -
Asymptomatic 284 (29.9%) 1.24 (0.75-2.03) 0.405 - -
CD4 cell count prior to LFU
ǂ, cells/mm
3 n = 945
> 350 557 (58.9%) 1.00 (REF) 1.00 (REF)
200-350 262 (27.7%) 1.39 (0.86-2.24) 0.174 1.64 (0.98-2.75) 0.060
< 200 126 (13.3%) 3.68 (2.25-6.03) < 0.001 1.99 (1.05-3.74) 0.034
Viral load prior to LFU
ǂ, copies/ml n = 939
≤ 400 825 (87.7%) 1.00 (REF) 1.00 (REF)
> 400 114 (12.1%) 6.46 (4.09-10.21) < 0.001 5.03 (2.95-8.57) < 0.001
* N values are for the number of patients included in univariate analysis. ǂ or prior to 31
st December 2006 for CCAs
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encompassing 93 clinical centres in Europe, Israel and
Argentina [24]), and the 16% reported in a survey of
community-based settings led by the American Founda-
tion of AIDS Research [25]. These differences were not
explained by significant variations in definitions of LFU,
as the majority defined LFU as patients who had not
been seen in a clinic for at least 12 months
[22-24,26-28].
However, the lower rates of LFU reported in one of
the French cohorts [21] may be due to the shorter, one-
year follow-up period compared with a cumulative LFU
rate over a nine-year period in our study. Our overall
high rate of loss to follow up also largely reflects the
high proportion (more than 50%) of migrants originat-
ing from sub-Saharan Africa or the Caribbean in our
clinic population, with high mobility and the highest
rates of loss to follow up. The medical records review
confirmed this, with documentation indicating that a
high proportion planned to leave the UK, either volunta-
rily or because of immigration problems. In contrast,
among white and black MSM, and white heterosexual
women and men, the rates of UKLFU were less than
18%.
It is possible that we may have overestimated the pro-
portion of HIV-infected patients LFU in the UK for
several reasons. There may have been difficulties obtain-
ing an exact match with the national SOPHID databases
because patients may have registered at another site
using a different date of birth or soundex code (either
due to registration using different identifiers or due to
coding differences, particularly in the transcribing and
coding of uncommon surnames). In addition, the num-
ber of patients LFU who were deceased may have been
underestimated since the national death register could
only match deceased patients younger than 60 years of
age. However, this would not have contributed signifi-
cantly to a mismatch since only 10 of 366 (< 3%)
UKLFU patients were older than 60 years.
F i n a l l y ,w ew e r eu n a b l et oc o n f i r mw h e t h e rp a t i e n t s
UKLFU in the UK had in fact left the country and were
either receiving ongoing care or had died in another
country. In approximately half of those with available
documentation, there was some indication that they
either intended to leave the UK or that there were
immigration problems, suggesting that they might have
been deported. However, this information was not col-
lected systematically, and was also available on only a
subset of patients, and should therefore be interpreted
with caution.
We found, overall, several independent risk factors
associated with an approximately two-fold increased risk
Table 3 Univariate & multivariate logistic regression for UKLFU vs. CCAs - NOT on HAART (n = 532)
n (%)* Univariate OR (95% CI ) P value Multivariate OR (95% CI) P value
Age at HIV clinic registration (per year older) n = 532 0.99 (0.97-1.01) 0.308 - -
Gender-ethnicity risk group n = 515
White MSM 106 (20.6 1.00 (REF) 1.00 (REF)
Black African/Caribbean MSM 25 (4.9%) 0.61 (0.23-1.67) 0.340 0.58 (0.17-1.94) 0.373
Black African heterosexual female 158 (30.7%) 1.67 (1.00-2.78) 0.048 1.57 (0.82-2.98) 0.172
Black African heterosexual male 66 (12.8%) 4.17 (2.17-8.03) < 0.001 3.91 (1.77-8.64) 0.001
Black Caribbean heterosexual female 30 (5.8%) 1.13 (0.48-2.62) 0.783 1.47 (0.55-3.90) 0.442
Black Caribbean heterosexual male 20 (3.9%) 2.38 (0.90-6.26) 0.080 2.16 (0.67-7.01) 0.199
White heterosexual female 16 (3.1%) 0.88 (0.29-2.74) 0.831 0.46 (0.09-2.38) 0.356
White heterosexual male 12 (2.3%) 0.65 (0.17-2.54) 0.534 1.91 (0.36-10.12) 0.448
Other 82 (15.9%) 1.68 (0.93-3.03) 0.086 1.48 (0.69-3.20) 0.318
Year of KCH HIV clinic registration n = 532 0.78 (0.74-0.84) < 0.001 0.75 (0.68-0.83) < 0.001
2003-2005 255 1.00 (REF) 1.00 (REF)
2000-2002 191 2.77 (1.88-4.09) < 0.001 2.91 (1.77-4.78) < 0.001
1997-1999 86 4.70 (2.78-7.94) < 0.001 5.26 (2.71-10.19) < 0.001
CDC stage prior to LFU
ǂ n = 495
AIDS 31 (6.3%) 1.00 (REF) 1.00 (REF)
Symptomatic 131 (26.5%) 0.40 (0.18-0.89) 0.025 0.83 (0.28-2.44) 0.732
Asymptomatic 333 (67.3%) 0.64 (0.30-1.33) 0.229 1.51 (0.52-4.41) 0.446
CD4 cell count prior to LFU
ǂ, cells/mm
3 n = 456
> 350 306 (67.1%) 1.00 (REF) 1.00 (REF)
200-350 103 (22.6%) 1.03 (0.65-1.64) 0.908 0.98 (0.58-2.44) 0.941
< 200 47 (10.3%) 3.55 (1.86-6.79) < 0.001 3.24 (1.49-7.04) 0.003
* N values are for the number of patients included in univariate analysis. ǂ or prior to 31st December 2006 for CCAs
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Page 7 of 10of being UKLFU: not receiving HAART; being a black
African man or woman; registering for care prior to
2003; being asymptomatic; and having a CD4 count of
less than 200 cells at last attendance. Our findings also
show some similarities and differences in risk factors
according to whether patients were receiving HAART or
not at the time of defaulting from care. Common to
both were an earlier clinic registration (before 2003) and
a CD4 cell count < 200 cells/mm
3. Among patients who
had not received HAART, those who were black African
h e t e r o s e x u a lm e nw e r ea l s om o r el i k e l yt ob eU K L F U ,
while among those on HAART, black African women
and those with a detectable viral load were at increased
risk of UKLFU.
These findings are consistent with those from several
clinical or research cohorts in North America and Europe,
which reported non-white ethnicity/migrants [21,22],
younger age [22-24], a CD4 cell count of less than 200
cells/mm
3 [22,24] or a high CD4 count being associated
with retention in care [25,26], non-use of HAART
[24,27,28], a detectable viral load [21,22,24,27,28] or
absence of an AIDS-defining illness as predictors of loss to
follow up [24-26].
Therefore, among both HAART recipients and non-
recipients, it is the most vulnerable patients who are
most likely to be lost to follow-up. Vulnerable patients
encompass those with advanced immunodeficiency, at
the highest risk of disease progression and in need of
ongoing care, as well as those on HAART, with poorly
controlled viraemia with the added risk for onward HIV
transmission of potentially HIV drug-resistant virus.
Our findings also show that black African men are the
most likely to default from care before receiving HAART,
consistent with studies from sub-Saharan Africa that
have highlighted the challenges of engaging African men
with HIV testing and clinical services [32-34]. In contrast,
among those receiving HAART, the highest probability of
loss to follow up was among African women (rather than
men). Of note, this was not explained by pregnant
women receiving short-term HAART for prevention of
mother to child transmission and then defaulting, as this
accounted for less than 10% of these women.
Figure 2 Loss to follow-up among 1859 clinic patients LFU defined as not seen for ≥ 1 year at the King’s College Hospital HIV clinic (up to
31
st December 2006). Transfers defined as LFU patients who subsequently have been seen elsewhere in the UK. UKLFU defined as LFU patients
not seen at any treatment site in the UK for ≥ 1 year. CCAs defined as patients who remained under King’s College Hospitals clinic follow-up as
of 31
st December 2006.
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Page 8 of 10In addition, the median follow up for UKLFU was
only 2.2 months for those not on HAART and 9.9
months for those recently prescribed HAART. This is
similar to the findings from patient cohorts from France
[23] and Italy [26], where the majority were LFU within
s i xm o n t h so fd i a g n o s i s .N e a r l yh a l fo fU K L F Up a t i e n t s
not yet on HAART had made two or less clinic visits
when they defaulted (usually following initial HIV test-
ing and diagnosis). This highlights the importance of
early supportive intervention in the weeks after initial
diagnosis in prevention of early defaulting from care.
Several important measures to minimize LFU have
been implemented at the clinic in the past 18 months.
These include: text messaging reminders to patients’
mobile phones the day before scheduled appointments;
reducing the number of initial clinic visits with different
members of the multi-disciplinary team following diag-
nosis; regular review of patients with missed appoint-
ments to allow early contact and intervention; and the
appointment of a peer-support worker. However, formal
prospective evaluation of the relative impact of these
different strategies to reduce loss to follow up among
HIV patients is now urgently needed in both developed
and resource-limited settings.
A further important implication of our findings of
high rates of loss to follow up is on the interpretation of
outcomes, such as toxicity, rates of virological suppres-
sion, adherence and mortality, reported from clinical
cohorts, which are based on those patients remaining in
follow up, and may therefore substantially overestimate
the proportion with a favourable outcome.
Conclusions
We observed a high rate of loss to follow up from our
HIV clinic in south London, and this was highest
among black African men and women. Our results high-
light the need to better understand the health-seeking
behaviours of patients LFU and to implement strategies
in HIV clinics for both better tracking and minimizing
of loss to follow up from HIV care.
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